Clinical trials: Cardiovascular Diseases Risk
Arrhythmias, Cardiac
Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone
The purpose of this retrospective observational study is to obtain information to confirm or contradict the results of prior studies on domperidone and sudden cardiac death.
- Trial name
- NCT00925457
- Testing
- No Intervention, Current Domperidone, Current proton pump inhibitor (PPI)
- Volunteers
- 1,608 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Coronary Artery Disease, Angina Pectoris
Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]
This study aim is to evaluate the additional effect of eicosapentaenoic acid and dose up effect of rosuvastatin for neoatherosclerosis in coronary artery disease patients.
- Trial name
- NCT03657758
- Testing
- EPA and rosuvastatin, High dose rosuvastatin
- Where
- Japan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Kobe University
Hypertension
Use of Beta-blockers and Risk of New Onset Diabetes
This study used an observational, retrospective cohort design to compare the presence and timing of new-onset diabetes (NOD) between hypertensive patients initiating therapy with carvedilol immediate-release (IR) and carvedilol…
- Trial name
- NCT01587638
- Testing
- carvedilol, cardio selective betablocker
- Volunteers
- 12,336 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia, Coronary Arteriosclerosis
Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)
This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe 10 mg coadministered with atorvastatin 10 mg versus atorvastatin 10 mg in Indonesian population with primary hypercholesterolemia.
- Trial name
- NCT00319449
- Testing
- Ezetimibe, Atorvastatin 10 mg
- Volunteers
- 22 people
- Sponsor
- Organon and Co
Traumatic Subdural Hematoma
Factors Influencing Readmission Rates of Acute Traumatic Subdural Hematoma in the Elderly
Acute traumatic subdural hematomas (TSDH) readmission rate is high (27.8%) with an increase in morbidity and cost for the elderly.
- Trial name
- NCT03878043
- Testing
- Follow-up Care
- Where
- United States
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Tarik Wasfie, MD
Carotid Atherosclerosis
Carotid Risk Prediction (CRISP) Consortium
Develop adverse event prediction and plaque phenotype classification models for patients with known or suspected carotid artery disease.
- Trial name
- CRISP (NCT04448353)
- Testing
- vascuCAP
- Where
- 5 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Elucid Bioimaging Inc.
Peptic Ulcer Disease
Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately
The purpose of this study is to investigate whether a fixed dose combination (FDC) capsule of esomeprazole 20 mg and acetylsalicylic acid (ASA) 81 mg has equivalent therapeutic efficacy compared to each of 2 free combinations of…
- Trial name
- NCT01015729
- Testing
- Esomeprazole/ASA Fixed Combination, Esomeprazole, ASA
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV Infections, Dyslipidemias
Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)
This is a phase 2, randomized, double-blinded, placebo-controlled clinical trial. The intervention drug will be efprezimod alfa (intravenous [IV] infusion).
- Trial name
- CALIBER (NCT03960541)
- Testing
- Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hypertriglyceridemia, Cardiovascular Diseases
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Trial name
- NCT03385239
- Testing
- ISIS 678354
- Where
- 31 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Akcea Therapeutics
Hypertension
Cardiovascular Risk Assessment in Patients Treated With Caduet
Compare the reduction in Framingham's predicted 10-year risk of a coronary event (6) in patients with hypertension and at least three other cardiovascular risk factors (including diabetic patients) seen in private practice and…
- Trial name
- RIGHT (NCT00297973)
- Testing
- Blood pressure measurements, Blood samples
- Where
- 384 sites in France
- Volunteers
- 1,442 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Aortic Valve Stenosis
Prizvalve Pro™ Transcatheter Aortic Valve Replacement Study
The purpose of this clinical trial is to evaluate the safety and efficacy of the Prizvalve Pro™ transcatheter aortic valve system in the treatment of patients with severe aortic stenosis who are at high risk of surgery or who are…
- Trial name
- NCT05864456
- Testing
- Prizvalve Pro™ transcatheter aortic valve system
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shanghai NewMed Medical Co., Ltd.
Atherosclerosis, Cardiovascular Disease
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased…
- Conditions
- Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
- Trial name
- CLARITY-CRP (NCT07783802)
- Testing
- Clazakizumab
- Where
- 46 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Heart Diseases, Postoperative Complications
A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass
The purpose of this study is to assess the safety of INO-1001, an intravenous PARP (poly-[ADP ribose] polymerase) inhibitor, in patients undergoing heart surgery.
- Trial name
- NCT00271167
- Testing
- INO-1001
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 162 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Acute Myocardial Infarction, Heart Failure
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF)…
- Trial name
- DAPA-MI (NCT04564742)
- Testing
- Dapagliflozin
- Where
- 103 sites in Sweden, United Kingdom
- Volunteers
- 4,017 people
- Sponsor
- AstraZeneca
Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
This is a pilot study of the Flow Medical Catheter, a catheter-based device used to deliver clot-dissolving medication directly to a blood clot in the lungs (pulmonary embolism).
- Trial name
- PE (NCT07681154)
- Testing
- Thrombolysis Catheter
- Volunteers
- 20 people
- Sponsor
- Flow Medical Solutions, Inc.
Diabetic Foot Ulcer (DFU)
Remote Temperature and Visual Monitoring To Help Manage Diabetic Foot Ulcers
This study is a prospective, observational investigation evaluating the effectiveness of Remote ThermoVisual Monitoring (RTVM) in the early detection of diabetic foot ulcers (DFUs) in high-risk populations.
- Trial name
- NCT06782386
- Testing
- OneStep Foot Scanner
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bluedrop Medical Limited
Dyslipidemia
A Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients.
This study is a local PCO sponsored, interventional, non-drug study to evaluate the efficacy of a health tele-counselling program in reducing cardiovascular risk in dyslipidemic patients.
- Trial name
- DISSEMINATE (NCT00708370)
- Testing
- COACH
- Where
- 22 sites in Malaysia
- Volunteers
- 297 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Myocardial Infarction
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart…
- Trial name
- NCT04509674
- Testing
- Empagliflozin
- Where
- 439 sites in United States, Argentina and 20 more
- Volunteers
- 6,522 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months).
- Trial name
- NCT06269120
- Testing
- Oral Semaglutide
- Where
- 19 sites in Hungary
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Coronary Artery Disease, High Bleeding Risk Patients
PaneLux PTCA : Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon
The propose of this study is to demonstrate, whenever using Drug Eluting Stent is not possible, the clinical security at 12 months, of the combinaison Bare Metal Stent plus Drug Eluting Balloon.
- Trial name
- PaneLux PTCA (NCT01930903)
- Testing
- Pantera Lux Drug Eluting Balloon
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Biotronik France